A new study suggests that a Web-based intervention could improve a cancer survivor’s cognitive function post treatment.
Cognitive impairment is a very common complaint among patients with cancer who have undergone chemotherapy. Now, a new study suggests that a Web-based intervention could improve a cancer survivor’s cognitive function.
Impaired cognitive function can impact a patient’s quality of life (QOL) and can result in depression, anxiety, and fatigue. In the absence of a documented correlation between neuropsychological testing results and cognitive symptoms, treatment remains a challenge. With the hope of addressing this issue, researchers in Australia have created a cognitive rehabilitation program: Insight.
The program was tested in 242 adult cancer survivors with a primary malignancy (not associated with the central nervous system) who had been treated with at least 3 cycles of adjuvant chemotherapy in the previous 6- to 60-month period. A complaint of persistent cognitive symptoms was a prerequisite for trial participation. While adjuvant endocrine treatments were permitted for patients with breast cancer, radiotherapy and targeted therapies had to be completed at least 3 months before participating in the study. Prior malignancy, diagnosis of an unstable psychiatric condition, and existing major cognitive disorder were grounds for exclusion.
Following a 30-minute phone consult, participants were randomly assigned (1:1) to a 15-week, home-based intervention or to standard care. Primary outcome for the trial was self-reported cognitive function (Functional Assessment of Cancer Therapy Cognitive Function [FACT-COG] perceived cognitive impairment [PCI] subscale), evaluated as the difference in function between the groups after completing a 15-week intervention (T2) and after 6 months (T3).
The researchers observed less PCI in the intervention group at T2 (P <.001), which was sustained at T3 (P <.001). At T2, significant difference in all the FACT-COG subscales were indicative of a successful intervention, the authors write. Further, levels of anxiety, depression, and fatigue were lower in the intervention group at T2, while stress was significantly lower at both time points. The intervention group also gained on QOL at the 6-month mark.
“The intervention, Insight, led to improvements in cognitive symptoms compared with standard care,” the authors conclude, “indicating that this intervention is a feasible treatment.”
Reference
Bray VJ, Dhillon HM, Bell ML, et al. Evaluation of a Web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy [published online October 28, 2016]. J Clin Oncol. doi: 10.1200/JCO.2016.67.8201.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More